What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Manish A. Shah spends much of his time researching Internal medicine, Cancer, Gastroenterology, Oncology and Surgery.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Placebo.
His Cancer research is multidisciplinary, incorporating elements of Disease, Cohort and Pathology.
His Gastroenterology research is multidisciplinary, relying on both Malignancy, Fluorouracil, Carcinoma, Docetaxel and Breast cancer.
Manish A. Shah has researched Oncology in several fields, including Regimen and Stomach.
His study explores the link between Surgery and topics such as Tolerability that cross with problems in Febrile neutropenia, Trastuzumab emtansine, Taxane, Pharmacokinetics and Biopsy.
His most cited work include:
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes (6309 citations)
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. (2779 citations)
- Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry (996 citations)
What are the main themes of his work throughout his whole career to date?
Manish A. Shah focuses on Internal medicine, Cancer, Oncology, Chemotherapy and Gastroenterology.
His biological study spans a wide range of topics, including Placebo and Surgery.
His Cancer study combines topics from a wide range of disciplines, such as Cancer research and Malignancy, Disease, Clinical trial, Pathology.
His Oncology study incorporates themes from Pembrolizumab, Irinotecan, Colorectal cancer, Docetaxel and Bevacizumab.
The Chemotherapy study combines topics in areas such as Randomized controlled trial and Trastuzumab.
His Gastroenterology research integrates issues from Gastroesophageal Junction Adenocarcinoma, Carcinoma and Metastasis.
He most often published in these fields:
- Internal medicine (65.91%)
- Cancer (45.96%)
- Oncology (42.68%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (65.91%)
- Oncology (42.68%)
- Cancer (45.96%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer, Pembrolizumab and Chemotherapy.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Placebo.
In his work, Intention-to-treat analysis, Performance status, Sudden death, Adverse effect and Progression-free survival is strongly intertwined with Clinical endpoint, which is a subfield of Gastroenterology.
The concepts of his Oncology study are interwoven with issues in Trastuzumab, MEDLINE, Phases of clinical research, Regimen and Biomarker.
His study brings together the fields of Cancer research and Cancer.
His Pembrolizumab study integrates concerns from other disciplines, such as PD-L1, Carcinoma, Gastroesophageal Junction Adenocarcinoma and Esophageal cancer.
Between 2018 and 2021, his most popular works were:
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. (125 citations)
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. (110 citations)
- Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2 (73 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Oncology, Pembrolizumab, Cancer and Advanced esophageal cancer.
His study in Gastroenterology extends to Internal medicine with its themes.
Manish A. Shah interconnects Hematology and MEDLINE in the investigation of issues within Oncology.
His Pembrolizumab research focuses on Esophageal cancer and how it connects with Adverse effect, Esophagus and Carcinoma.
His study in the fields of PD-L1 and Immunotherapy under the domain of Cancer overlaps with other disciplines such as 2019-20 coronavirus outbreak.
His Advanced esophageal cancer research also works with subjects such as
- Treatment options, Second line treatment and Chemotherapy regimen most often made with reference to Second-line therapy,
- Clinical trial that connect with fields like Survival rate and Randomized controlled trial,
- Poor prognosis that intertwine with fields like Psycho-oncology, Health knowledge, Intensive care medicine and Advanced cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
